EP0655924A1 - COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION - Google Patents

COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION

Info

Publication number
EP0655924A1
EP0655924A1 EP93906955A EP93906955A EP0655924A1 EP 0655924 A1 EP0655924 A1 EP 0655924A1 EP 93906955 A EP93906955 A EP 93906955A EP 93906955 A EP93906955 A EP 93906955A EP 0655924 A1 EP0655924 A1 EP 0655924A1
Authority
EP
European Patent Office
Prior art keywords
combination
erbb
antibodies
antibody
gpl85
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93906955A
Other languages
German (de)
English (en)
Other versions
EP0655924A4 (fr
Inventor
Philip G. Kasprzyk
Charles R. King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncologix Inc
Original Assignee
Oncologix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncologix Inc filed Critical Oncologix Inc
Publication of EP0655924A1 publication Critical patent/EP0655924A1/fr
Publication of EP0655924A4 publication Critical patent/EP0655924A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a combination o monoclonal antibodies capable of preventing and treatin tumors. More specifically, the monoclonal antibodies ar single chain monoclonal antibodies which are capable o treating and preventing tumors.
  • erbB-2 gen also called HER-2 or neu
  • One object of Applicant's invention relates to combination of at least two monoclonal antibodies capable treating or preventing human malignancies wherein t malignant cells overexpress gpl85 ⁇ .
  • the combinati comprises at least a first and second antibody each of whi recognizes the gpl85 extracellular domain of erbB-2.
  • T activity demonstrated by the combination antibody treatme has shown greater activity than expected by the sum of t individual antibodies at the same overall antibo concentration.
  • Another object of the present invention provides f the use of monoclonal antibodies which are single cha monoclonal antibodies.
  • the single chain antibodies can used to form a bispecific antibody.
  • FIG. 1A Specificity of monoclonal antibodies # and #23.
  • Subconfluent SK-Br-3 monolayers were metabolical labeled with 35S-Cys (spec. act. 1000 Ci/m ol).
  • Total cel proteins were immunoprecipitated with 10 ⁇ g of the indicat antibodies.
  • the immune complexes were recovered by Protei G Agarose (Genex, Gaithersburg, MD) and analyzed by SDS-PA on an 8- 16% Tri s-Glycine gel . The gel was exposed to fi l at -70°C overnight with an intensifying screen .
  • Figure IB gpl85 overexpression in the gastri cell line N87 and a tumor from N87 mouse xenografts compare to high and low gpl85erbB—2 overexpressers. Cells or tumo were lysed in sample buffer which contained 0.125
  • Detection of gpl85 was performed with a monoclona antibody to the c-terminal portion of the protein.
  • FIG. lC Southern blot analysis of the erbB-2 gen in N87 (gastric), SK-Br-3 (breast), and SK-OV-3 (ovarian cell lines and human placenta.
  • DNA was extracted from cel lines and human placenta tissue using guanidine thiocyanat and cesium gradient centrifugation.
  • DNA (15 ⁇ g) was cleave with restriction enzyme HinDIII, separated b electrophoresis on a 1% agarose gel, transferred t nitrocellulose, and probed with radioactive erbB-2 cDN probe as previously described (26).
  • the cDNA prob corresponds to the entire erbB-2 protein coding region.
  • Figure 2 Effects of Ab#21 and Ab#23 on the growth o human N87 gastric tumor cells in a monolayer MTT growt assay.
  • PBS, Ab#21, Ab#23 or combination of Ab#21 and Ab#23 at the indicate concentration were then added.
  • the plates were grown a 37°C in a 5% CO. humidified atmosphere.
  • FIG. 3A Effects of treatment with Ab#21 ( ) Ab#23( ), a combination of Ab#21 and Ab#23 ( ) , or PB ( ) on the growth of N87 tumor xenografts in BNX mice
  • Tumor cells (5 X 10 /mouse) were subcutaneously injecte into the flanks of BNX (beige, nude, xid) mice.
  • Treatmen begun on day 1 consisted of four trial groups (3 mice pe group) each given 0.2 ml intraperitoneal injections twice week of either PBS ( ) , 200 ⁇ g purified Ab#21 (0), 200 ⁇ purified Ab#23 ( ) , or a mixture of 100 ⁇ g purified Ab#2 and 100 ⁇ g of purified Ab#23 ( ) for three weeks. Tumo growth is reported as an average relative tumor volume ⁇ .e.m. ⁇ 15%. Two repeats of the experiment gave the sam results.
  • Figure 3B Effect of treatment after the formation o small tumors.
  • Cells were injected using the same treatmen protocol as above except for the fact the treatment wa begun 4 days after cell injection instead of 1 day after Animal care was in accordance with institutional guidelines
  • Figure A Effect of antibody binding on erbB- protein turnover.
  • Subconfluent N87 cell monolayers were pulse-labeled 1 h with 20 ⁇ Ci 35S-Cysteine and then chase with 5 mM Cys in the presence of Ab#21 alone, Ab#23 alone or a 1:1 combination of Ab#21 and Ab#23 (10 ⁇ g/ml)for 24 h
  • Total cellular protein was immunoprecipitated as describe in Figure 1 using a monoclonal antibody directed against th c-terminus of gpl85 coupled to Sepharose and analyzed by SDS-PAGE. The gel was exposed to film at -70°C overnight with an intensifying screen.
  • Figure 4B Measurement of tyrosine phosphorylation of gp!85 ⁇ after incubation with antibody combination.
  • Cells were plated as in Figure 4A. After 1 h cells were processed as in Figure IB.
  • the proteins were electroblotted onto nitrocellulose paper and incubated with anti-phosphotyrosine IgG (polyclonal, Upstate Biotechnology, Inc.) and immunodetected using an ECL western blotting detection system (Amersham) . The film was exposed for 5 min at room temperature.
  • FIG. 5 Effects of Ab#21 and Ab#23 on the growth of human Calu-3 lung adenocarcinoma tumor cells in a monolayer MTT growth assay.
  • a single cell suspension of 10,000 cells/well was plated in a chemically defined medium consisting of RPMI-1640 supplemented with Insulin (5 ⁇ g/ml), human transferrin (10 ⁇ g/ml) , 17- ⁇ -estradiol (10 nM), sodium selenite (5 nM), and 10 mM Hepe ⁇ .
  • PBS, Ab#21, Ab#23 or a combination of Ab#21 and Ab#23 at the indicated concentration were then added.
  • the plates were grown at 37°C in a 5% CO- humidified atmosphere.
  • FIG. 6 Effects of Ab#23 and Ab#94 on the growth of human Calu-3 lung adenocarcinoma tumor cells in a monolayer MTT growth assay.
  • a single cell suspension of 10,000 cells/well was plated in a chemically defined medi consisting of RPMI-1640 supplemented with Insulin (5 ⁇ g/ml human transferrin (10 ⁇ g/ml), 17- ⁇ -estradiol (10 nM), sodi selenite (5 nM), and 10 mM Hepes.
  • PBS, Ab#23, Ab#94 or combination of Ab#21 and Ab#23 at the indicat concentration were then added.
  • the plates were grown 37°C in a 5% C0 2 humidified atmosphere.
  • Figure 7 The cDNA sequence for the *single cha anti-erbB2 antibody, Ab#23.
  • Figure 8 The cDNA sequence for the *single cha anti-erbB2 antibody, Ab#21 (e22).
  • One object of the present invention is a combination at least two monoclonal antibodies, which is capable preventing and treating human malignancies, wherein t malignant cells overexpress gpl85 ⁇ and wherein said least two different antibodies each recognize a differe epitope of the gpl85 expression product of erbB-2, therefo the antibodies do not cross react with each other.
  • embodiment of the present invention provides for t combination to comprise first and second antibodies whi are preferably combined such that the resulting ratio of t first to second is effective for decreasing the expressi product of the erbB-2 gene.
  • a convenient method f measuring the expression product of erbB-2 gene may be found in Figure 4A.
  • the decrease in the expression of the erbB-2 gene product is the result of the combination decreasing the half life of erbB-2 protein in the cell.
  • the combination of the antibodies has the characteristic trait of essentially not increasing the tyrosine phosphorylation of gpl85 expression product.
  • An example of a first to second antibodies ratio having the activity necessary to decrease the expression product of the erbB-2 gene comprises a ratio of from about 1:2 to about 2:1. Preferably, such a ratio is 1:1.
  • the present invention is not intended to be limited to the antibody ratios discussed herein. The fact that other ratios are effective and may yield higher activity than the 1:1 ratio used as an example is recognized and acknowledged by the inventors as being within the scope of this invention.
  • Figures 1A-C, 2 and 3A, B The activity of this combination is exemplified in Figures 1A-C, 2 and 3A, B as follows.
  • Figure 1A-C demonstrate that the N87 cells overexpress the gpl85 erbB-2 protein as a result of erbB-2 gene amplification.
  • Figure 2 shows that a combination of Ab#21 and Ab#23 inhibits the growth of N87 cells dji vitro. Similar results have been demonstrated using the combination of Ab#23 and Ab#94 as well as Ab#23 and Ab#21, on the growth of human Calu-3 lung adenocarcinoma (See Figures 5 and 6).
  • Figure 3A and B show the activity of combinations of Ab#21 and Ab#23 inhibiting and reversing the growth of N87 cells growing as tumors in immunodeficient mice. These results indicate the general nature of the application of combinations of antibodies.
  • the antibodies against the erbB2 gene encoded product used in this invention can be designed as chimeric antibodies.
  • Chimeric antibodies have variable region (antigen binding regions) of nonhuman (e.g., murine) origi and constant regions of human origin. Because they ar predominantly human, chimeric antibodies are les immunogenic in humans, which can help overcome problem associated with administering foreign proteins to humans.
  • the antibodies of the present inventio may be produced through genetic recombination or th Kohler-Milstein hybridoma method for production o antibodies. It is also recognized that fragments, analogue or derivatives of the antibodies themselves can be utilize in this invention in place of the entire antibody.
  • Another object of the present invention provides fo antibodies against erbB-2 gene encoded product which ar designed as single chain antibodies.
  • a single chai antibody is one in which the light and heavy variabl regions of the antibody are linked together to form a singl chain antibody. It is contemplated in this application tha a combination of these antibodies include antibodies whic are combined as an admixture as discussed above an antibodies which are combined to form a bispecific antibody
  • a bispecific antibody is an artificially produce antibody usually comprised of two single chain antibodie each of which is recognizes a different antigen bindin site.
  • huma malignancies which may be treated or prevented using th present invention
  • adenocarcinonas of the breast, ovary lung and stomach are examples of some of the huma malignancies which may be treated or prevented using th present invention.
  • Another embodiment of applicants' invention provides method for preventing and eradicating the human malignancie described above.
  • the method involves administering to patient an effective dose of a combination of anti-erbB- antibodies to achieve an effective concentration of the antibody combination at the tumor site; for example, a concentration of at least l ⁇ g/ml.
  • concentration at the tumor site does not exceed about lO ⁇ g/ml.
  • the combination is administered in a dose from about .1 mg/kg to about 10 mg/kg of body weight.
  • Another embodiment of Applicants' invention provides for the antibody combination to be used in passive tumor therapy, wherein an effective dose of the antibody combination is administered in or with a pharmaceutically acceptable vehicle to a patient afflicted with a human malignancy overexpressing gpl85erbB-2.
  • a pharmaceutically acceptable vehicle examples include non-toxic buffers, physiological saline, etc.
  • Applicants' invention also provides for at least one of the antibodies of the antibody combination to be used as a component of an immunotoxin.
  • at least one antibody of the combination can be linked to an anti-cancer pharmaceutical or a cytotoxin to form an immunotoxin.
  • Various pharmaceutical or cytotoxic agents can be chemically or genetically coupled to the combination.
  • radioactive compounds e.g., isotopes of Boron and Rhenium
  • agents which bind DNA such as alkylating agents or various antibodies (e.g., daunomysin, adriamycin, chlorambucil)
  • anti-metabolites e.g., methotrexate
  • inhibitors of protein synthesis e.g., diphtheria toxin and toxic plant proteins.
  • Administration to a patient of an effective dose of the combination of antibodies described herein may be accomplished via chronic intraveneous administration for period of time sufficient to result in the regression o eradication of the human malignancy being treated
  • Administration of the combination may also be accomplishe in a patient by direct injection or delivery of th combination to the tumor site. Such administration would b of sufficient duration and concentration to result i eradication or reduction of the tumor.
  • tw antibody combination acts by constraining gpl85 er " int an activated conformation thus mimicking an agonist ligand If the two antibody combination mimics the ligand, the treatment using the combination should result in increase gpl85 ⁇ autophosphorylation.
  • Anti-phosphotyrosin immunoblots were used to test this hypothesis. As shown i Figure 4B, no increase in tyrosine phosphorylation o gpl85 er ⁇ from N87 cells was observed 1 or 2 hours afte the addition of the antibody combination or up to 24 h o treatment. This suggests that the antibody combination doe not increase the autophosphorylation of gpl85 an therefore does not act to inhibit the activity of th tyrosine kinase.
  • results demonstrate that a combination o anti-receptor antibodies leads to different and more poten anti-tumor activities than single antibodies.
  • results indicate that the combination antibod therapy is a useful approach to treatment of huma ___ *hR malignancies overexpressing gpl85 This approach may b particularly important in the treatment of gastric cancer, disease which responds poorly to current systemi chemotherapies.
  • a source of human erbB-2 protein we used a NIH/3T cell engineered to express the human erbB-2 protein on it surface (N/erbB-2).
  • Membrane preparations of these cell were prepared by hypotonic lysis in 2mM Hepes pH 7.4, removal of nuclei by centrifugation at 5,000 x g an isolation of membranes by centrifugation at 100,000 x g.
  • Mice were immunized with lOO ⁇ g of N/erbB-2 membran preparation in a 50:50 mix of adjuvant in 200 ⁇ l.
  • Adjuvan was Freund's complete for the first injection followed b Freund' ⁇ incomplete adjuvant. Mice were given intraperitoneal injections over 4 weeks.
  • ELISA reaction was develope using peroxidase coupled goat anti-mouse antibody an standard methods. Hybridoma cultures secreting a anti-erbB-2 antibody were subjected to two rounds of singl cell cloning and identification of positive subclones b ELISA as described above.
  • Monoclonal antibodies directed against th erbB-2 extracellular domain of gpl85 were tested for specifi reaction to N/erbB-2 cell membranes in an ELISA assay. Tw of these designated Ab#21 and Ab#23 after screening i growth assays exhibited the highest biological activity an were used in this study. Antibodies were isolated in larg amounts from ascites fluid and purified by HPLC with
  • N87 tumor xenografts The efficacy of combination antibody therapy was teste on the growth of N87 tumor xenografts.
  • One inoculation o five million N87 cells were injected subcutaneou ⁇ ly int nude mice produce rapidly growing tumors, with a shor latency. Tumor growth at the injection site was easil quantitated.
  • the N87 cells did no form tumors in the animals treated twice a week for thre weeks with a total of 200 ⁇ g of antibodies per injectio with the combination of Ab#21 and Ab#23. In sharp contras they were potently tumorigenic in animals treated with th
  • each monoclonal antibody alone may hav limited activity to partially restrict the rate of tumo growth.
  • the activity exhibited by the combinatio far exceeded the cumulative effect expected from th combination.
  • Th activation of the murine neu oncogene is accomplished b point mutation as evidenced by qualitative interference i the structure and function of the neu gene, whereas th human erbB-2 oncogene is activated by overexpres ⁇ ion o erbB-2, a quantitative interference of the apparently norma protein which results in tumor formation.
  • Antibodies #21; Ab#23; and Ab#94 have been deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, USA. Ab#21 was deposited on and given ATCC # . Ab#23 was deposited on and given ATCC # . Ab#94 was deposited on and given ATCC # .
  • cDNA was prepared using random primer (N & ) (Boerhinger Mannheim).
  • the immunoglobulin light and heavy chain clones were isolated using PCR and the primers: light chain, 5' CAC GTC GAC ATT CAG CTG ACC CAC TCT CCA and GAT GGA TCC AGT TGG TGC AGC ATC3*; heavy chain 5'C GGA ATT TCA GGT TCT GCA GIA GTC WGG3' and 5' AGC GGA TCC AGG GGC CAG TGG ATA GAC3' [G,A,C, stand for standard nucleotides; I for inosine, W for A
  • the light and heavy chain coding regions were joined by synthetic linker GSTSGSGKSSEGKG specified by overlappin oligonucleotides as described.
  • the intact scFv codin region was inserted in frame with an E.coli OMPA leade sequence under direction of the lambda P_ promoter
  • cDNA wa prepared using random primer (N ⁇ ) (Boerhinger Mannheim) The immunoglobulin light and heavy chain clones were isolated using PCR and the primers: light chain, 5' CAC GT GAC ATT CAG CTG ACC CAC TCT CCA and GAT GGA TCC AGT TGG TG AGC ATC3'; heavy chain 5'C GGA ATT TCA GGT TCT GCA GIA GT WGG3' and 5' AGC GGA TCC AGG GGC CAG TGG ATA GAC3* [G,A,C, stand for standard nucleotides; I for inosine, W for A o T] .
  • the products of the PCR reaction wre cloned into PUC18 Linkage into a scFv was by PCR giving the individual ligh and heavy cDNA clones and 4 oligonucleotides 5' - cgagatgagtccagctgacccagtctc 5' - gaagatttaccagaaccagaggtagaaccttttatttccagcttgga 5' - ctggttctggtaaatcttctgaaggtaaggtgtgcagctgcaggag 5' - cgagtgcaagcttaggagacggtgaccgt.
  • the light and heavy chain coding regions were joined by synthetic linker GSTSGSGKSSEGKG specified by overlappi oligonucleotides as described.
  • the intact scFv codi region was inserted in frame with an E.coli OMPA lead sequence under direction of the lambda P. L_ promote

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison d'au moins deux anticorps monoclonaux agissant à titre préventif et curatif sur les tumeurs malignes chez l'homme, caractérisées par une expression excessive de gp185erbB-2. Les anticorps monoclonaux de la combinaison reconnaissent différents épitopes du produit d'expression gp185 de erbB-2. De ce fait il n'y a pas de réaction croisée des anticorps. De préférence, la combinaison diminue le produit d'expression du gène erbB-2. Dans une autre forme d'exécution, la combinaison n'augmente pas fondamentalement la phosphorylation de la tyrosine du produit d'expression gp185.
EP93906955A 1992-06-30 1992-10-21 COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION. Withdrawn EP0655924A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90655592A 1992-06-30 1992-06-30
US906555 1992-06-30
PCT/US1992/008545 WO1994000136A1 (fr) 1992-06-30 1992-10-21 COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION

Publications (2)

Publication Number Publication Date
EP0655924A1 true EP0655924A1 (fr) 1995-06-07
EP0655924A4 EP0655924A4 (fr) 1996-09-11

Family

ID=25422648

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93906955A Withdrawn EP0655924A4 (fr) 1992-06-30 1992-10-21 COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION.

Country Status (6)

Country Link
EP (1) EP0655924A4 (fr)
JP (1) JPH08504172A (fr)
KR (1) KR100269879B1 (fr)
AU (1) AU687346B2 (fr)
CA (1) CA2120745A1 (fr)
WO (1) WO1994000136A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733752B1 (en) 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1947119A3 (fr) 1997-12-12 2012-12-19 Genentech, Inc. Traitement du cancer avec un anticorps Anti-ERBB2 combiné à une chimiothérapie
EP1941905A1 (fr) 1998-03-27 2008-07-09 Genentech, Inc. Synergie d'anticorps APO-2 ligand-anti-her-2
CA2704600C (fr) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. Methode de production d'anticorps avec activite adcc accrue
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BR0012196A (pt) 1999-06-25 2002-03-19 Genentech Inc Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
WO2001076630A1 (fr) * 2000-04-06 2001-10-18 Kyowa Hakko Kogyo Co., Ltd. Diagnostics et remedes contre la polyarthrite rhumatoide
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
CA2407556C (fr) 2000-05-19 2011-06-21 Genentech, Inc. Analyse de detection genique permettant d'ameliorer la probabilite d'une reponse efficace a une therapie du cancer basee sur un antagoniste d'erbb
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP2289942B1 (fr) 2002-04-10 2013-07-31 Genentech, Inc. Variantes d'anticorps anti-HER2
WO2004008099A2 (fr) 2002-07-15 2004-01-22 Genentech, Inc. Procedes d'identification de tumeurs sensibles a un traitement par anticorps anti-erbb2
CN100408097C (zh) * 2002-10-10 2008-08-06 默克专利有限公司 双特异性抗erb-b抗体及其在肿瘤治疗中的用途
WO2004032961A1 (fr) * 2002-10-10 2004-04-22 Merck Patent Gmbh Anticorps bispecifiques contre erb utilises en therapie antitumorale
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP2478912B1 (fr) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Conjugués d'auristatin avec des anticorps dirigés contre le HER2 ou le CD22 et leur usage thérapeutique
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
DK1771482T3 (da) 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
EP1850874B1 (fr) 2005-02-23 2013-10-16 Genentech, Inc. Extension de la periode menant à la progression de la maladie ou à la survie chez les patients atteints du cancer de l'ovaire par le pertuzumab
US8350011B2 (en) 2006-08-04 2013-01-08 Medimmune Limited Antibodies to ErbB2
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010022736A2 (fr) 2008-08-29 2010-03-04 Symphogen A/S Compositions de l'anticorps de recombinaison anti-récepteur du facteur de croissance anti-épidermique egfr
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011130580A1 (fr) 2010-04-15 2011-10-20 Alper Biotech, Llc Anticorps monoclonaux contre antigènes her2 et leurs utilisations
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
WO2012069466A1 (fr) 2010-11-24 2012-05-31 Novartis Ag Molécules multi-spécifiques
KR101574864B1 (ko) 2010-12-21 2015-12-11 에프. 호프만-라 로슈 아게 이소폼이 농축된 항체 제제 및 그의 제조 방법
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2751285B2 (fr) 2011-08-31 2020-04-01 Genentech, Inc. Procédé d'analyse de la sensibilité d'une tumeur à des inhibiteurs de la egfr kinase
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
US11058768B2 (en) 2014-04-16 2021-07-13 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
EP3303373B1 (fr) 2015-05-30 2020-04-08 Molecular Templates, Inc. Supports de sous-unité a de toxine de shiga, déimmunisés, et molécules de ciblage de cellule les comprenant
CN107787331B (zh) 2015-06-17 2022-01-11 豪夫迈·罗氏有限公司 抗her2抗体和使用方法
EP3567049A4 (fr) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation Récepteur antigénique chimérique et cellules tueuses naturelles exprimant celui-ci
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
EP3560945A1 (fr) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Procédés de purification de polypeptides utilisant des polysorbates
WO2020035577A1 (fr) 2018-08-16 2020-02-20 Cantargia Ab Compositions d'anticorps anti-il1rap
WO2023044483A2 (fr) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement du cancer positif her2
GB202309703D0 (en) 2023-06-27 2023-08-09 Epsilogen Ltd Composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867962A (en) * 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
WO1991005264A1 (fr) * 1989-09-29 1991-04-18 Oncogenetics Partners Detection et quantification des proteines apparentees neu dans les liquides biologiques des humains

Also Published As

Publication number Publication date
KR100269879B1 (ko) 2000-10-16
JPH08504172A (ja) 1996-05-07
EP0655924A4 (fr) 1996-09-11
WO1994000136A1 (fr) 1994-01-06
AU3773393A (en) 1994-01-24
CA2120745A1 (fr) 1994-01-06
AU687346B2 (en) 1998-02-26
KR950700075A (ko) 1995-01-16

Similar Documents

Publication Publication Date Title
EP0655924A1 (fr) COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION
AU2001239913B2 (en) Method of treating cancer with anti-neurotrophin agents
Baselga et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
US6224868B1 (en) Reagent and processes for targeting mutant epidermal growth factor receptors
Tokuda et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
AU2001295002B2 (en) Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
AU782994C (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7811566B2 (en) Antibody-induced apoptosis
CN108424454B (zh) 靶向egf受体的单克隆抗体175及其衍生物和用途
US20150132308A1 (en) Combination Therapy Using Anti-EGFR And Anti-HER2 Antibodies
AU2001239913A1 (en) Method of treating cancer with anti-neurotrophin agents
KR20010071271A (ko) 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
KR20020069104A (ko) 항-ＥｒｂＢ２ 항체를 사용한 전립선암의 치료방법
KR20120062942A (ko) 항-ＥｒｂＢ２ 항체를 이용한 치료 방법
MXPA02002037A (es) Dosificaciones para el tratamiento con anticuerpos anti-erb2.
EA018717B1 (ru) Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение
US20030202973A1 (en) Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
Ohnishi et al. Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody
CN115814105A (zh) 抗体药物偶联物的用途及联合用药物及其用途
IL300388A (en) Treatment with drug-conjugated antibodies specific for the HER2 site
HK40085220A (en) Antibody drug conjugate formulation and use thereof
BR112013010764A2 (pt) composição de anticorpos anti-her3, molécula de ligação biespecífica, molécula de ácido nucleico, vetor de expressão, linhagem celular policlonal, método para produção da referida composição, composição farmacêutica e uso da referida composição

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: A61K 35/14

RHK1 Main classification (correction)

Ipc: C12N 15/13

A4 Supplementary search report drawn up and despatched

Effective date: 19960726

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 20000712

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010123